Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.

Autor: Hamilton E; Department of Medical Oncology, Sarah Cannon Research Institute, Nashville, Tennessee., Galsky MD; Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York., Ochsenreither S; Department of Hematology, Oncology and Cancer Immunology, Charité Comprehensive Cancer Center, Berlin, Germany., Del Conte G; Department of Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy., Martín M; Department of Medical Oncology, Hospital Gregorio Maranon, Madrid, Spain., De Miguel MJ; Early Phase Clinical Trial Unit, START Madrid CIOCC HM Sanchinarro, Madrid, Spain., Yu EY; Department of Medicine, Fred Hutchinson Cancer Center and University of Washington, Seattle, Washington., Williams A; Clinical Research, Sarah Cannon Research Institute, London, United Kingdom., Gion M; Department of Medical Oncology, Hospital Ruber International, Madrid, Spain.; Ramón y Cajal University Hospital, Madrid, Spain., Tan AR; Department of Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina., Agrawal L; Department of Medical Oncology, Norton Cancer Institute, Louisville, Kentucky., Rutten A; Department of Medical Oncology, GZA Hospitals Campus Sint-Augustinus, Antwerp, Belgium., Machiels JP; Department of Medical Oncology, Institut Roi Albert II Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (UC Louvain, IREC), Brussels, Belgium., Cresta S; Division of Medical Oncology, Department of Oncology and Hematology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Debruyne PR; Kortrijk Cancer Centre, General Hospital AZ Groeninge, Kortrijk, Belgium.; Medical Technology Research Centre (MTRC), School of Life Sciences, Anglia Ruskin University, Cambridge, United Kingdom.; School of Nursing and Midwifery, University of Plymouth, Plymouth, United Kingdom., Hennequin A; Department of Medical Oncology, Centre Georges Francois Leclerc, Dijon, France., Moreno V; Early Phase Trials Unit, START Madrid-FJD, Fundacion Jimenez Diaz, Madrid, Spain., Minchom A; Drug Development Unit, Royal Marsden Hospital, Sutton, United Kingdom., Valdes-Albini F; Division of Medical Oncology, Department of Medicine, University of Miami Hospital & Clinics, Sylvester Comprehensive Cancer Center, Miami, Florida.; Department of Medical Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida., Petrylak D; Division of Genitourinary Oncology, Yale University, New Haven, Connecticut., Li L; Quantitative Clinical Pharmacology, Daiichi Sankyo, Inc., Basking Ridge, New Jersey., Tsuchihashi Z; Department of Translational Science, Daiichi Sankyo, Inc., Basking Ridge, New Jersey., Suto F; Department of Translational Science, Daiichi Sankyo, Inc., Basking Ridge, New Jersey., Cheng FC; Biostatistics and Data Management, Daiichi Sankyo, Inc., Basking Ridge, New Jersey., Kandil M; CSPV, Daiichi Sankyo, Inc., Basking Ridge, New Jersey., Barrios D; Department of Global Oncology R&D, Daiichi Sankyo, Inc., Basking Ridge, New Jersey., Hurvitz S; Department of Medicine, Fred Hutchinson Cancer Center and University of Washington, Seattle, Washington.; Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Dec 16; Vol. 30 (24), pp. 5548-5558.

Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial.

Autor: Shitara K; National Cancer Center Hospital East, Kashiwa, Japan. kshitara@east.ncc.go.jp.; Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan. kshitara@east.ncc.go.jp., Bang YJ; Seoul National University College of Medicine, Seoul, Republic of Korea., Iwasa S; National Cancer Center Hospital, Tokyo, Japan., Sugimoto N; Osaka International Cancer Institute, Osaka, Japan., Ryu MH; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Sakai D; Osaka International Cancer Institute, Osaka, Japan., Chung HC; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea., Kawakami H; Kindai University Hospital, Osaka, Japan., Yabusaki H; Niigata Cancer Center Hospital, Niigata, Japan., Sakamoto Y; Osaki Citizen Hospital, Osaki, Japan., Nishina T; National Hospital Organization Shikoku Cancer Center, Ehime, Japan., Inaki K; Daiichi Sankyo Co. Ltd, Tokyo, Japan., Kuwahara Y; Daiichi Sankyo Inc., Basking Ridge, NJ, USA., Wada N; Daiichi Sankyo RD Novare Co. Ltd, Tokyo, Japan., Suto F; Daiichi Sankyo Inc., Basking Ridge, NJ, USA., Arita T; Daiichi Sankyo Co. Ltd, Tokyo, Japan., Sugihara M; Daiichi Sankyo Co. Ltd, Tokyo, Japan., Tsuchihashi Z; Daiichi Sankyo Inc., Basking Ridge, NJ, USA., Saito K; Daiichi Sankyo Inc., Basking Ridge, NJ, USA., Kojima A; Daiichi Sankyo Co. Ltd, Tokyo, Japan., Yamaguchi K; Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

Publikováno v: Nature medicine [Nat Med] 2024 Jul; Vol. 30 (7), pp. 1933-1942. Date of Electronic Publication: 2024 May 14.

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.

Autor: Smit EF; Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, Netherlands. Electronic address: e.f.smit@LUMC.nl., Felip E; Department of Oncology, Vall d'Hebron University and Vall d'Hebron Institute of Oncology, Barcelona, Spain., Uprety D; Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA., Nagasaka M; University of California Irvine, School of Medicine, Orange, CA, USA., Nakagawa K; Department of Medical Oncology, Kindai University, Osaka-Sayama, Japan., Paz-Ares Rodríguez L; Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain., Pacheco JM; Department of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Li BT; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Planchard D; Department of Medical Oncology, Thoracic Cancer Group, Gustave Roussy, Villejuif, France., Baik C; Department of Medical Oncology, University of Washington, Seattle, WA, USA., Goto Y; National Cancer Center Hospital, Tokyo, Japan., Murakami H; Shizuoka Cancer Center, Shizuoka, Japan., Saltos A; Moffitt Cancer Center, Tampa, FL, USA., Pereira K; Daiichi Sankyo, Basking Ridge, NJ, USA., Taguchi A; Daiichi Sankyo, Tokyo, Japan., Cheng Y; Daiichi Sankyo, Basking Ridge, NJ, USA., Yan Q; Daiichi Sankyo, Basking Ridge, NJ, USA., Feng W; Daiichi Sankyo, Basking Ridge, NJ, USA., Tsuchihashi Z; Daiichi Sankyo, Basking Ridge, NJ, USA., Jänne PA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2024 Apr; Vol. 25 (4), pp. 439-454.

151P Baseline circulating tumor DNA (ctDNA) biomarker analysis of patients with human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic non–small cell lung cancer (NSCLC) treated with trastuzumab deruxtecan (T-DXd)

Autor: Smit, E.F., Felip, E., Uprety, D., Nagasaka, M., Nakagawa, K., Paz-Ares, L., Pacheco, J., Li, B.T., Planchard, D., Baik, C.S., Goto, Y., Murakami, H., Pereira, K.M.C., Taguchi, A., Kogo, M., Kuwahara, Y., Zou, M., Feng, W., Tsuchihashi, Z., Jänne, P.A.

Publikováno v: In Annals of Oncology October 2023 34 Supplement 2:S241-S242

Progress in high throughput SNP genotyping methods.

Autor: Tsuchihashi, Z, Dracopoli, N C

Publikováno v: Pharmacogenomics Journal. 2002, Vol. 2 Issue 2, p103. 8p.